Print
contact ussite map
Juvaris Beotherapeutics, Inc.

Juvaris BioTherapeutics’ Universal Influenza Vaccine Protects from Lethal H1N1 and H3N2 Challenges in Pre-Clinical Studies

Data to be Presented at the Annual Meeting of the American Association of Immunologists

Burlingame, CA - May 8, 2009

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines and immunotherapeutics for infectious diseases and cancer, today announced results demonstrating that its universal influenza vaccine produces robust antibody responses and complete protection in H1N1 and H3N2 pre-clinical challenge models. A universal vaccine would protect against both epidemic virus strains mismatched with the annual seasonal vaccine and new pandemic threats like the H1N1 swine flu and could be stockpiled. Data on Juvaris’ vaccine platform will be presented at the 96th Annual Meeting of the American Association of Immunologists (AAI) taking place May 7-12, 2009 in Seattle, Wash.

Juvaris’ universal flu vaccine is composed of conserved antigenic epitopes for both influenza A and B strains combined with its proprietary adjuvant, JVRS-100. The objective of a universal influenza vaccine is to improve the reliability and quality of protection by raising cross-protective immunity to all strains of influenza. Juvaris’ universal influenza vaccine has demonstrated significant induction of immunity with a novel construct of M2e, which is a conserved sequence found on all influenza A strains. Juvaris has a rationally designed, synthetic tetrameric M2e-peptide antigen that when combined, even at extremely low doses, with the JVRS-100 adjuvant has shown significant induction of Th-1 biased antibody responses that have proven to be highly protective. These M2e-specific antibodies targeting the induction of IgG2a subclass antibodies contribute significantly to antibody-dependent cellular cytotoxicity (ADCC) compared with IgG1 subclass antibodies produced by a Th-2 response. ADCC is the primary mechanism of protection believed to be required to yield a successful universal flu vaccine. In murine challenge models, the vaccine has conferred significant protection from highly lethal strains of influenza A (H1N1, H3N2).

Detailed results from the universal influenza vaccine program along with other Juvaris programs will be presented at the following poster sessions at AAI:

  • JVRS-100 Adjuvanted Universal Influenza A Vaccine Based on a Multiple Antigenic Peptide of M2e Protects from Lethal Challenge (Program #132, Abstract #6)
  • Skin Delivery of JVRS-100 With and Without a Trivalent Inactivated Influenza Vaccine Results in Potent Adaptive Immune Responses (Program #78, Abstract #34)
  • Cationic Lipid-DNA Complex Adjuvant (JVRS-100) Combined with Heat-Inactivated Whole Virion Influenza Vaccine Confers Protection Against Homotypic and Heterosubtypic Lethal Challenge (Program #132, Abstract #1)
  • Interleukin-12 p40 and p35 Subunit Production Coincides with Inverse Relationship Between Innate and Acquired Immune Responsiveness in Mice Initially Dosed with JVRS-100 (Program #134, Abstract #42)

About JVRS-100
JVRS-100 is a cationic lipid-DNA complex that is being developed as an adjuvant to improve the effectiveness of existing vaccines and to develop new vaccines against a variety of infectious diseases. Research indicates that the mechanism of action of JVRS-100 is distinct from other known adjuvants. The adjuvant complex self-assembles with disease-specific antigens and induces substantial antibody- and cell-mediated immune responses, particularly induction of CD4+ and CD8+ T lymphocytes. Immunological responses elicited by the lipid-DNA complexes have been successfully demonstrated in both prophylactic and therapeutic vaccine settings in multiple species. This platform provides the opportunity to develop many disease-specific immunotherapy products for which there are significant unmet medical needs.

About Juvaris
Juvaris BioTherapeutics, Inc. is a clinical stage company developing adjuvanted vaccines and immunotherapeutics to treat infectious diseases and cancer. The Company's lead product candidate, JVRS-100, is currently in clinical development as an adjuvant to improve the efficacy of seasonal influenza vaccines in the elderly population. The Company is also developing vaccines for HSV-2, universal flu and pandemic flu. Juvaris completed a Series A financing led by Kleiner Perkins Caufield & Byers and has been awarded multiple NIH grants.

Company Contact:
Grant E. Pickering
Juvaris BioTherapeutics, Inc.
866 Malcolm Road, Suite 100
Burlingame, California
650-259-1800 ext. 227
gpickering@juvaris.com

© 2014 Juvaris BioTherapeutics.